Neurological Sciences Department, Federico II University, Naples, Italy
Hermitage Capodimonte IDC, Naples, Italy
Biostructure and Bioimaging Institute, National Research Council, Naples, Italy
Diagnostic Imaging Department, Federico II University, Naples, Italy
Department of Neurological Sciences, Second University of Naples, Naples, Italy
References: Polman, C.H., O'connor, P.W., Havrdova, E., A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis (2006) N Engl J Med, 354, pp. 899-91
Yousry, T.A., Major, E.O., Ryschkewitsch, C., Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy (2006) N Engl J Med, 354, pp. 924-933
(2006), http://www.emea.europa.eu/humandocs/PDFs/EPAR/tysabri/H, European Medicine Agency.-603-en6.pdf (accessed 27 June 2006)Rudick, R.A., Stuart, W.H., Calabresi, P.A., Natalizumab plus interferon-β 1a for relapsing multiple sclerosis (2006) N Engl J Med, 354, pp. 911-923
Klawiter, E.C., Cross, A.H., Naismith, R.T., The present efficacy of multiple sclerosis therapeutics: is the new 66% just the old 33%? (2009) Neurology, 12, pp. 984-990
Poser, C.M., Paty, D.W., Scheinberg, L., New diagnostic criteria for multiple sclerosis: guidelines for research protocols (1983) Ann Neurol, 13, pp. 227-231
Mcdonald, W.I., Compston, A., Edan, G., Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis (2001) Ann Neurol, 50, pp. 121-127
Lublin, F.D., Reingold, S.C., Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis (1996) Neurology, 46, pp. 907-911
Jacobs, L.D., Cookfair, D.L., Rudick, R.A., Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: The Multiple Sclerosis Collaborative Research Group (MSCRG) (1996) Ann Neurol, 39, pp. 285-294
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Lancet, 352, pp. 1498-1504
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I: clinical results of a multimember, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group (1993) Neurology, 43, pp. 655-661
Johnson, K.P., Brooks, B.R., Cohen, J.A., Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial: The Copolymer 1 Multiple Sclerosis Study Group (1995) Neurology, 45, pp. 1268-1276
Noseworthy, J.H., Ebers, G.C., Vandervoort, M.K., Farquhar, R.E., Yetisir, E., Roberts, R., The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial (1994) Neurology, 44, pp. 16-20
(2006), Nota AIFA. Determinazione/C n. 115/2006 (GU n. 292 del 16-12-2006)Putzki, N., Yaldizli, O., Bühler, R., Schwegler, G., Curtius, D., Tettenborn, B., Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland (2010) Eur Neurol, 63, pp. 101-106
Belachew, S., Phan-Ba, R., Bartholomé, E., Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis (2011) Eur J Neurol, 18, pp. 240-245
Outteryck, O., Ongagna, J.C., Zéphir, H., Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice (2010) J Neurol, 257, pp. 207-211
Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: A head-to-head retrospective study